7 June 2017 - Burtomab, a drug for metastatic neuroblastoma, has been granted breakthrough therapy designation by the FDA for the treatment of paediatric patients with relapsed or refractory neuroblastoma with central nervous system or leptomeningeal metastasis.

Burtomab, a drug for metastatic neuroblastoma, created by Memorial Sloan Kettering Cancer Center and licensed to Y-mAbs Therapeutics has been granted breakthrough therapy designation by the FDA for the treatment of paediatric patients with relapsed or refractory neuroblastoma with central nervous system or leptomeningeal metastasis. 

MSK’s Nai-Kong Cheung, MD, PhD, created and tested the antibody that resulted in the breakthrough therapy designation.

Read Y-mAbs Therapeutics press release